NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:33271
Who is this for?
Show terms as
View depth
15Active trials8Treatment centers

Where are you in your journey?

UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data

What is NON RARE IN EUROPE: Non-alcoholic fatty liver disease?

Non-alcoholic fatty liver disease (NAFLD) is a condition where too much fat builds up in the liver in people who drink little or no alcohol. It is one of the most common liver conditions in the world. NAFLD covers a range of problems, from simple fat buildup (called steatosis or 'fatty liver') to a more serious form called non-alcoholic steatohepatitis (NASH), where the liver becomes inflamed and damaged. Over time, NASH can lead to scarring of the liver (fibrosis or cirrhosis) and, in some cases, liver failure or liver cancer. Many people with NAFLD have no symptoms at all, especially in the early stages. When symptoms do appear, they can include tiredness, mild discomfort or pain in the upper right side of the belly, and feeling generally unwell. NAFLD is closely linked to obesity, type 2 diabetes, high blood pressure, and high cholesterol — a group of conditions sometimes called metabolic syndrome. Treatment mainly focuses on lifestyle changes such as losing weight, eating a healthier diet, exercising regularly, and managing related conditions like diabetes and high cholesterol. There are currently very few approved medications specifically for NAFLD, though several are being studied. In advanced cases, a liver transplant may be needed. Early detection and lifestyle changes can significantly slow or even reverse the disease.

Also known as:

Key symptoms:

Fatigue or low energyDull ache or discomfort in the upper right side of the abdomenUnexplained weight gain, especially around the bellyFeeling generally unwellEnlarged liver (found on scan or exam)Yellowing of the skin or eyes (jaundice) — in advanced diseaseSwollen belly due to fluid buildup (ascites) — in advanced diseaseEasy bruising or bleeding — in advanced diseaseSwollen legs or ankles — in advanced diseaseConfusion or difficulty thinking clearly (hepatic encephalopathy) — in severe cases

Inheritance
Multifactorial
Caused by a mix of several genes and environmental factors
Age of Onset
Variable
Can begin at different ages, from infancy through adulthood
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jul 2026GLP-1 RA on Liver OMICS in MASLD

Medical College of Wisconsin

TrialNOT YET RECRUITING
Mar 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

GlaxoSmithKline — PHASE1

TrialRECRUITING
Feb 2026Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

Institute of Liver and Biliary Sciences, India — NA

TrialNOT YET RECRUITING
Feb 2026Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease

The Affiliated Hospital of Hangzhou Normal University — NA

TrialNOT YET RECRUITING
May 2025Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules

Dong Hui — PHASE2

TrialNOT YET RECRUITING
Feb 2025Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

Steno Diabetes Center Copenhagen — NA

TrialNOT YET RECRUITING
Nov 2024Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET

Rigshospitalet, Denmark — NA

TrialACTIVE NOT RECRUITING
Jun 2024Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

Zhujiang Hospital — PHASE4

TrialRECRUITING
May 2024Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)

Charite University, Berlin, Germany — NA

TrialRECRUITING
May 2024Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis

Western University, Canada — NA

TrialNOT YET RECRUITING

Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for NON RARE IN EUROPE: Non-alcoholic fatty liver disease.

15 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

15 recruitingView all trials with filters →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Phase 31 trial
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Phase 3
Active — not recruiting
PI: Rebecca Taub, MD (Madrigal Pharmaceuticals, Inc.) · Sites: Birmingham, Alabama; Chandler, Arizona +69 more · Age: 18+ years
Phase 42 trials
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
Phase 4
Actively Recruiting
PI: Hong Chen, MD (Zhujiang Hospital) · Sites: Guangzhou, Guangdong · Age: 18–75 yrs
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Phase 4
Actively Recruiting
PI: Umar Raja, MBBS (Shifa International Hospital) · Sites: Peshawar, KPK · Age: 18–65 yrs
Phase 12 trials
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Phase 1
Actively Recruiting
PI: GSK Clinical Trials (GlaxoSmithKline) · Sites: Auckland · Age: 18–55 yrs
Bicalutamide Therapy in Young Women With NAFLD and PCOS
Phase 1
Actively Recruiting
PI: Monika A Sarkar, MD, MAS (University of California, San Francisco) · Sites: San Francisco, California · Age: 18–42 yrs
N/A8 trials
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
N/A
Active — not recruiting
PI: Jennifer Price, MD, PhD (University of California, San Francisco) · Sites: Tuscaloosa, Alabama; La Jolla, California +6 more · Age: 18+ years
Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.
N/A
Actively Recruiting
· Sites: Castellana Grotte, BARI · Age: 18–60 yrs
Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET
N/A
Active — not recruiting
· Sites: Copenhagen · Age: 18–70 yrs
Effects of Phytosterol Supplementation on Liver Function and Inflammatory Status in Patients with Nonalcoholic Fatty Liver Disease
N/A
Active — not recruiting
· Sites: Amman · Age: 18–70 yrs
Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)
N/A
Actively Recruiting
· Sites: Berlin · Age: 35–70 yrs
Characteristics of NAFLD Among Type 2 Diabetes Patients
N/A
Active — not recruiting
PI: Geert Robaeys, prof. dr. (Hasselt University) · Sites: Genk · Age: 18–80 yrs
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
N/A
Actively Recruiting
PI: André Marette, PhD (Laval University) · Sites: Québec, Quebec · Age: 18–75 yrs
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
N/A
Actively Recruiting
PI: Timothy R Morgan, MD (VA Long Beach Healthcare System) · Sites: Long Beach, California · Age: 18–75 yrs
Other2 trials
The European NAFLD Registry
Actively Recruiting
PI: Quentin M Anstee, MBBS, PhD (Newcastle University) · Sites: Antwerp; Helsinki +35 more · Age: 18+ years
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
Actively Recruiting
PI: WEI Lyu (Department of Infectious Diseases, PekingUMCH) · Sites: Beijing, Beijing Municipality

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

No specialists are currently listed for NON RARE IN EUROPE: Non-alcoholic fatty liver disease.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to NON RARE IN EUROPE: Non-alcoholic fatty liver disease.

Search all travel grants →NORD Financial Assistance ↗

Community

Open NON RARE IN EUROPE: Non-alcoholic fatty liver diseaseForum →

No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Non-alcoholic fatty liver disease.

Start the conversation →

Latest news about NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for NON RARE IN EUROPE: Non-alcoholic fatty liver disease.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage of NAFLD do I have, and how much liver damage is there?,Do I need a liver biopsy, or can my condition be monitored with scans and blood tests?,How much weight do I need to lose to improve my liver health, and what support is available to help me?,Should I be tested or treated for related conditions like diabetes, high cholesterol, or high blood pressure?,Are there any medications I should avoid because of my liver condition?,Am I a candidate for any new medications like resmetirom, or are there clinical trials I could join?,How often do I need follow-up tests, and what signs should prompt me to seek urgent care?

Common questions about NON RARE IN EUROPE: Non-alcoholic fatty liver disease

What is NON RARE IN EUROPE: Non-alcoholic fatty liver disease?

Non-alcoholic fatty liver disease (NAFLD) is a condition where too much fat builds up in the liver in people who drink little or no alcohol. It is one of the most common liver conditions in the world. NAFLD covers a range of problems, from simple fat buildup (called steatosis or 'fatty liver') to a more serious form called non-alcoholic steatohepatitis (NASH), where the liver becomes inflamed and damaged. Over time, NASH can lead to scarring of the liver (fibrosis or cirrhosis) and, in some cases, liver failure or liver cancer. Many people with NAFLD have no symptoms at all, especially in the

How is NON RARE IN EUROPE: Non-alcoholic fatty liver disease inherited?

NON RARE IN EUROPE: Non-alcoholic fatty liver disease follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease?

Yes — 15 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Non-alcoholic fatty liver disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Frequently asked questions about NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is NON RARE IN EUROPE: Non-alcoholic fatty liver disease?

    NON RARE IN EUROPE: Non-alcoholic fatty liver disease is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:33271). It is typically inherited as multifactorial. Age of onset is generally variable. For verified primary sources, see the UniteRare NON RARE IN EUROPE: Non-alcoholic fatty liver disease page.

  2. How is NON RARE IN EUROPE: Non-alcoholic fatty liver disease inherited?

    NON RARE IN EUROPE: Non-alcoholic fatty liver disease follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for NON RARE IN EUROPE: Non-alcoholic fatty liver disease?

    Approved treatments for NON RARE IN EUROPE: Non-alcoholic fatty liver disease are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials recruiting for NON RARE IN EUROPE: Non-alcoholic fatty liver disease?

    UniteRare currently lists 15 clinical trials relevant to NON RARE IN EUROPE: Non-alcoholic fatty liver disease sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.

  5. How do I find a specialist for NON RARE IN EUROPE: Non-alcoholic fatty liver disease?

    Verified NON RARE IN EUROPE: Non-alcoholic fatty liver disease specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.

See full NON RARE IN EUROPE: Non-alcoholic fatty liver disease page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.